CD8 TIL cell therapy (Applied Immune Sciences/RPR Gencell)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameCD8 TIL cell therapy (Applied Immune Sciences/RPR Gencell)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tumor Infiltrating Lymphocytes
Mechanisms of ActionUpdating
TargetsNot applicable
Therapy Area/IndicationsCarcinoma, Renal Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesApplied Immune SciencesSanofi
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesApplied Immune SciencesSanofi
Active IndicationsN/A
Inactive IndicationsCarcinoma, Renal Cell

Other Information

ATC CodeN/A
Related LinksN/A